Primary and secondary prevention trials in Alzheimer disease: Looking back, moving forward

Current Alzheimer Research

Volumn 14, Issue 4, 2017, Pages 426-440

  Hsu, David ^a,b   Marshall, Gad A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alzheimer disease; Anxiety; Hypertension; Neuropsychological; Pathophysiology

Indexed keywords

ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; ESTROGEN; PROGESTERONE;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; COORDINATION; DIET SUPPLEMENTATION; HUMAN; INTERVENTION STUDY; LIFESTYLE MODIFICATION; MEDICAL ETHICS; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVENTION STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; STANDARDIZATION; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; CLINICAL TRIAL (TOPIC);

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; SECONDARY PREVENTION;

EID: 85015691754     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160930112125     Document Type: Review

References (86)

1. Alzheimer Association 2014. Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement10: e47-e92 (2014).
2. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. New Engl J Med 368(14): 1326-34 (2013).
3. Association. Changing the Trajectory of Alzheimer’s Disease: A National Imperative, USA: Alzheimer’s Association (2010).
4. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 281(12): 1112-20 (1999).
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265(24): 3255-64 (1991).
6. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37(6): 1583-633 (2006).
7. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 42(1): 227-76 (2011).
8. Force USPST. Screening for Cognitive Impairment in Older Adults 2014 [September 21, 2014]; Available from: uspreventiveservicestaskforce.org.
9. Mrazek PJ, Haggerly RJ. Eds. Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. USA: National Academies Press (1994).
10. U.S. Department of Health and Human Services. National Plan to Address Alzheimer’s Disease: Update 2014. USA: ASPE (2014).
11. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7(3): 270-9 (2011).
12. Jack CR, Jr., Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7(3): 257-62 (2011).
13. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7(3): 263-9 (2011).
14. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7(3): 280-92 (2011).
15. Jack CR, Jr., Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol 71(6): 765-75 (2012).
16. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimer’s Dement 8(1): 1-13 (2012).
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7): 939-44 (1984).
18. Selkoe DJ. Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann New York Acad Sci 924: 17-25 (2000).
19. Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, et al. Can we prevent Alzheimer’s disease? Secondary “prevention” trials in Alzheimer’s disease. Alzheimer’s Dement 9(2): 123-31 e1 (2013).
20. Carrillo MC, Rowe CC, Szoeke C, Masters CL, Ames D, O’Meara T, et al. Research and standardization in Alzheimer’s trials: reaching international consensus. Alzheimer’s Dement 9(2): 160-8 (2013).
21. Knopman DS, Jack CR, Jr., Wiste HJ, Weigand SD, Vemuri P, Lowe V, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78(20): 1576-82 (2012).
22. Karran E, Hardy J. Antiamyloid therapy for Alzheimer’s disease--are we on the right road? New Eng J Med 370(4): 377-8 (2014).
23. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. New Eng J Med 370(4): 311-21 (2014).
24. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Trans Med 6(228): 228fs13 (2014).
25. Grill JD, Karlawish J, Elashoff D, Vickrey BG. Risk disclosure and preclinical Alzheimer’s disease clinical trial enrollment. Alzheimer’s Dement 9(3): 356-9 e1 (2013).
26. Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology 77(15): 1487-93 (2011).
27. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer’s disease. New Eng J Med 368(13): 1169-71 (2013).
28. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352(9137): 1347-51 (1998).
29. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev (2): CD003160 (2009).
30. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326): 7-22 (2002).
31. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346): 1623-30 (2002).
32. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 10(11): 969-77 (2011).
33. Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA 174(3): 324-33 (2014).
34. Feart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues JF, et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA 302(6): 638-48 (2009).
35. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300(9): 1027-37 (2008).
36. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 302(6): 627-37 (2009).
37. Verghese J, Lipton RB, Katz MJ, Hall CB, Derby CA, Kuslansky G, et al. Leisure activities and the risk of dementia in the elderly. New Engl J Med 348(25): 2508-16 (2003).
38. Valenzuela M, Sachdev P. Can cognitive exercise prevent the onset of dementia? Systematic review of randomized clinical trials with longitudinal follow-up. Am J Geriatr Psychiatry 17(3): 179-87 (2009).
39. Papp KV, Walsh SJ, Snyder PJ. Immediate and delayed effects of cognitive interventions in healthy elderly: a review of current literature and future directions. Alzheimer’s Dement 5(1): 50-60 (2009).
40. Ball K, Berch DB, Helmers KF, Jobe JB, Leveck MD, Marsiske M, et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 288(18): 2271-81 (2002).
41. Willis SL, Tennstedt SL, Marsiske M, Ball K, Elias J, Koepke KM, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA 296(23): 2805-14 (2006).
42. Rebok GW, Ball K, Guey LT, Jones RN, Kim HY, King JW, et al. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc 62(1): 16-24 (2014).
43. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 3(6): 343-53 (2004).
44. Fratiglioni L, Wang HX, Ericsson K, Maytan M, Winblad B. Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet 355(9212): 1315-9 (2000).
45. Richard E, Andrieu S, Solomon A, Mangialasche F, Ahtiluoto S, Moll van Charante EP, et al. Methodological challenges in designing dementia prevention trials - the European Dementia Prevention Initiative (EDPI). J Neurol Sci 322(1-2): 64-70 (2012).
46. Richard E, Van den Heuvel E, Moll van Charante EP, Achthoven L, Vermeulen M, Bindels PJ, et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord 23(3): 198-204 (2009).
47. Kivipelto M, Solomon A, Ahtiluoto S, Ngandu T, Lehtisalo J, Antikainen R, et al. The finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER): study design and progress. Alzheimer’s Dement 9(6): 657-65 (2013).
48. Solomon AL, Soininen E, Tuomilehto H, Lindstrom J, Lehtisalo J, A multidomain, two-year, randomized controlled trial to prevent cognitive impairment: The finger study. Alzheimer’s Dement 10(4): P137-P8 (2014).
49. Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B, et al. Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer’s disease. Alzheimer’s Dement 5(2): 114-21 (2009).
50. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 43(8): 1609-11 (1993).
51. Group AR, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68(21): 1800-8 (2007).
52. Group AR, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, et al. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65(7): 896-905 (2008).
53. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimer’s Dement 7(4): 402-11 (2011).
54. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG, Team AR. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer’s Disease Antinflammatory Prevention Trial. Int J Geriatr Psychiatry 27(4): 364-74 (2012).
55. Alzheimer’s Disease Anti-inflammatory Prevention Trial Research G. Results of a follow-up study to the randomized Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimer’s Dement 9(6): 714-23 (2013).
56. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev (1): CD003122 (2008).
57. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289(20): 2651-62 (2003).
58. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 291(24): 2947-58 (2004).
59. Espeland MA, Brunner RL, Hogan PE, Rapp SR, Coker LH, Legault C, et al. Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women’s Health Initiative study of cognitive aging extension. J Am Geriatr Soc 58(7): 1263-71 (2010).
60. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300(19): 2253-62 (2008).
61. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11(10): 851-9 (2012).
62. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol 5(3): 140-52 (2009).
63. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer’s Dement 6(6): 456-64 (2010).
64. Sperling RA, Jack CR, Jr., Aisen PS. Testing the right target and right drug at the right stage. Sci Trans Med 3(111): 111cm33 (2011).
65. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimer’s Dement 8(4): 261-71 (2012).
66. Sperling RA, Jack CR, Jr., Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer’s Dement 7(4): 367-85 (2011).
67. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, et al. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimer’s Dis 26(3): 321-9 (2011).
68. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM, Jaramillo-Elorza MC, Moreno S, Aguirre-Acevedo DC, et al. Predementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet Neurol 10(3): 213-20 (2011).
69. A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease, Including a Placebo-Treated Noncarrier Cohort [July 24, 2014]. Available from: http://www.clinicaltrials.gov/show/NCT01998841.
70. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11(7): 597-604 (2012).
71. Friedrich MJ. Researchers test strategies to prevent Alzheimer disease. JAMA 311(16): 1596-8 (2014).
72. Caselli RJ, Dueck AC, Huentelman MJ, Lutz MW, Saunders AM, Reiman EM, et al. Longitudinal modeling of cognitive aging and the TOMM40 effect. Alzheimer’s Dement 8(6): 490-5 (2012).
73. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, et al. Disclosure of APOE genotype for risk of Alzheimer’s disease. New Engl J Med 361(3): 245-54 (2009).
74. Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimer’s Res Ther 5(5): 48 (2013).
75. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. New Engl J Med 367(9): 795-804 (2012).
76. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer’s Disease Caused by a Genetic Mutation (DIAN-TU) [July 22, 2014]; Available from: http://www.clinicaltrials.gov/show/NCT01760005.
77. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69(2): 198-207 (2012).
78. Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 9(1): 54-8 (2013).
79. Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4) [July 24, 2014]. Available from: http://clinicaltrials.gov/show/NCT02008357.
80. Lingler JH, Klunk WE. Disclosure of amyloid imaging results to research participants: has the time come? Alzheimer’s Dement 9(6): 741-4 e2 (2013).
81. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 71(8): 961-70 (2014).
82. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer’s disease. Pharmacog J 10(5): 375-84 (2010).
83. Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer’s Disease (AD) and Safety and Efficacy of Pioglitazone in Delaying Its Onset [July 24, 2014]; Available from: http://clinicaltrials.gov/show/NCT01931566.
84. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68(1): 45-50 (2011).
85. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32(9): 1626-33 (2011).
86. Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020. Cold Spring Harbor Perspect Med 2(11): pii a011585 (2012).